Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Moxidectin Compared With Ivermectin in Onchocerciasis Endemic Areas
NCT04311671Phase 3Completed
- Sponsor
- Medicines Development for Global Health
- Start
- May 2021
- Primary completion
- Sep 2024
- Modality
- Allosteric Modulators
- Countries
- 2
01
Overview
A Phase 3 trial of moxidectin in onchocerciasis, sponsored by Medicines Development for Global Health. Started May 2021; status: completed.
02
Drugs
moxidectin
03
Conditions
onchocerciasis
Beyond the preview
Go deeper on NCT04311671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04311671.